Oncogenesis and mutagenesis of pituitary tumors

Adam M. Sonabend, Wael Musleh, Maciej S. Lesniak*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Although pituitary tumors may be present in up to 10% of the population, the pathophysiology of these lesions is not well characterized. Pituitary tumors are composed of monoclonal cell populations with disrupted control of replication pathways. The oncogenes and tumor suppressor genes that are common in other malignancies (i.e. jun, fos, myc, and p53) are rarely involved in the development of these tumors. However, oncogenes, such as gsp, can be present in up to 40% of hormonally active adenomas. The process of pituitary oncogenesis further appears to involve oncogenes such as cyclin E, cyclin D1, and the pituitary tumor transforming gene (PITG). Finally, the cAMP signaling cascade plays a significant role in generation of both benign and malignant pituitary tumors. In this review, the biology of pituitary adenomas is explored with a special emphasis on potential targets for the development of targeted therapeutics.

Original languageEnglish (US)
JournalExpert Review of Anticancer Therapy
Issue number9 SUPPL.
StatePublished - Sep 1 2006


  • Adenoma
  • Biology
  • Chromosome
  • Genetics
  • Hypophysis
  • Oncogene
  • Pathophysiology
  • Pituitary
  • Syndrome
  • Tumor suppressor gene

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Oncogenesis and mutagenesis of pituitary tumors'. Together they form a unique fingerprint.

Cite this